Domestic pressures behind Daewoong's Chinese acquisition?
This article was originally published in Scrip
Executive Summary
The South Korean firm Daewoong Pharmaceutical is acquiring the Chinese pharma manufacturer Liaoning Baifeng for KRW18bn ($16.1m), with an eye out to increasing its export business in Asia and eventually other developed markets.